文献速递神经肿瘤

瑞士成人胶质母细胞瘤中的下一代测序:多中心决策分析

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
PubMed 文献 · J Neurooncol · 2022-04-29

该调查纳入瑞士全部8家神经肿瘤初级诊疗中心,分析新诊断胶质母细胞瘤中下一代测序(NGS)的应用及决策标准,采用客观共识法分析决策树的一致性与差异。8家中心中7家开展NGS,最相关决策标准为年龄、标准治疗适用性和体能状态,NGS最常用于60岁以下不适合标准治疗的体能较好患者,但至今极少改变治疗过程。

要点

  • 瑞士8家神经肿瘤中心中7家对新诊断胶质母细胞瘤患者开展NGS。
  • 决策最相关标准为年龄、标准治疗适用性和体能状态。
  • NGS最常用于60岁以下不适合标准治疗的体能较好患者,极少用于一般健康状况差者。

核心结论

  • NGS在瑞士成人神经肿瘤中心胶质母细胞瘤中应用频繁,但至今极少改变治疗过程。

研究设计与样本

  • 基于调查的多中心决策分析,瑞士全部8家神经肿瘤初级诊疗中心参与。
  • 调查内容包括所用NGS检测方法及新诊断胶质母细胞瘤中应用NGS的标准。
  • 采用客观共识方法分析决策树的一致性与差异。

主要发现

  • 8家中心中7家对新诊断胶质母细胞瘤患者开展NGS,使用自制或市售检测。
  • 决策最相关的标准为年龄、标准治疗适用性和体能状态。
  • NGS最常用于60岁以下不适合标准治疗的体能较好患者,极少用于一般健康状况差的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland. METHODS: All eight primary care centres for Neuro-Oncology in Switzerland participated in this survey. The NGS assays used as well as the criteria for the application of NGS in newly diagnosed glioblastoma were investigated. Decision trees were analysed for consensus and discrepancies using the objective consensus methodology. RESULTS: Seven out of eight centres perform NGS in patients with newly diagnosed glioblastoma using custom made or commercially available assays. The criteria most relevant to decision making were age, suitability of standard treatment and fitness. NGS is most often used in fitter patients under the age of 60 years who are not suitable for standard therapy, while it is rarely performed in patients in poor general health. CONCLUSION: NGS is frequently applied in glioblastomas in adults in Neuro-Oncology centres in Switzerland despite seldom changing the course of treatment to date.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zeitlberger AM, Putora PM, Hofer S, et al. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. J Neurooncol. 2022. PMID: 35486306. doi:10.1007/s11060-022-04022-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。